甲氨蝶呤联合生物制剂对比生物制剂单药治疗类风湿关节炎:随机试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入16项随机试验共4965例类风湿关节炎患者,评估甲氨蝶呤联合已批准生物制剂对比生物制剂单药的疗效与安全性。结果显示联合治疗6个月时ACR50应答率相对提高32%(RR 1.32,95%CI 1.20-1.45,P<0.001),相当于每100例多11例应答(7-16例);因不良事件停药风险可能增加20%(RR 1.21,95%CI 0.97-1.50,P=0.09),相当于每100例多1例(0-3例),均为中等质量证据。
要点
- 联合甲氨蝶呤可使6个月ACR50应答率相对提高32%,绝对获益为每100例多7-16例。
- 因不良事件停药风险可能增加20%,但差异未达统计学显著性(P=0.09)。
- 中等质量证据支持生物制剂治疗时联用甲氨蝶呤而非单药治疗。
核心结论
- 随机试验提供中等质量证据支持类风湿关节炎患者使用生物制剂时联用甲氨蝶呤而非单药治疗,获益-风险平衡有利。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、CENTRAL等数据库,纳入16项随机试验共4965例患者。
- 纳入评估生物制剂联合甲氨蝶呤对比同一生物制剂单药的随机试验,涵盖除阿那白滞素和certolizumab外的所有已批准用于RA的生物制剂。
- 采用随机效应模型进行荟萃分析,计算风险比及95%置信区间,并使用GRADE方法评估证据质量。
主要发现
- 联合治疗6个月时ACR50应答的总体可能性相对提高32%(RR 1.32,95%CI 1.20-1.45,P<0.001),相当于每100例多11例应答(7-16例),中等质量证据。
- 因不良事件停药的风险在联合治疗中可能增加20%(RR 1.21,95%CI 0.97-1.50,P=0.09),相当于每100例多1例(0-3例),中等质量证据。
关键数值与推荐
- ACR50应答:联合治疗对比生物制剂单药的RR为1.32(95%CI 1.20-1.45,P<0.001)。
- 因不良事件停药:联合治疗对比生物制剂单药的RR为1.21(95%CI 0.97-1.50,P=0.09)。
临床怎么用
- 在处方生物制剂治疗类风湿关节炎时,支持联用甲氨蝶呤而非单药治疗,以改善6个月ACR50应答。
- 需权衡联合治疗可能轻度增加的不良事件停药风险,但绝对增加幅度较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy and safety of methotrexate (MTX) in combination with an approved biological agent compared to biological monotherapy, in the management of patients with rheumatoid arthritis (RA). METHODS: MEDLINE, EMBASE, CENTRAL and other sources were searched for randomised trials evaluating a biological agent plus MTX versus the same biological agent in monotherapy. Co-primary outcomes were ACR50 and the number of patients who discontinued due to adverse events (AEs). Random-effects models were applied for meta-analyses with risk ratio and 95% confidence intervals and the GRADE approach was used to assess confidence in the estimates. RESULTS: The analysis comprised 16 trials (4965 patients), including all biological agents approved for RA except anakinra and certolizumab. The overall likelihood of responding to therapy (i.e. ACR50) after 6 months was 32% better when MTX was given concomitantly with biological agents (1.32 [1.20-1.45]; P < 0.001) corresponding to 11 more out of 100 patients (7-16 more); Moderate Quality Evidence. Discontinuing due to AEs from concomitant use of MTX was potentially 20% increased (1.21 [0.97-1.50]; P = 0.09) compared to biological monotherapy corresponding to 1 more out of 100 patients (0-3 more); Moderate Quality Evidence. CONCLUSIONS: Randomised trials provide Moderate Quality Evidence for a favourable benefit-harm balance supporting concomitant use of MTX rather than monotherapy when prescribing a biological agent in patients with RA although in absolute terms only 7-16 more out of 100 patients will achieve an ACR50 response after 6 months of this combination therapy.
引用
- Tarp S, Jørgensen TS, Furst DE, et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2018. PMID: 30396592. doi:10.1016/j.semarthrit.2018.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。